LCL 161

Drug Profile

LCL 161

Alternative Names: LCL-161; NVP-LCL161; Second Mitochondria-derived Activator of Caspases (SMAC) mimetic - Novartis Oncology; SMAC mimetic LCL161

Latest Information Update: 17 Feb 2017

Price : $50

At a glance

  • Originator Novartis
  • Developer Mayo Clinic; National Cancer Institute (USA); Novartis; Novartis Oncology; SCRI Development Innovations; US Oncology Research
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Inhibitor of apoptosis protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Multiple myeloma; Myelofibrosis
  • Phase I/II Ovarian cancer; Small cell lung cancer
  • Phase I Cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 03 Dec 2016 Efficacy and adverse events data from a phase II trial in Myelofibrosis presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-2016)
  • 26 Oct 2016 Phase-I clinical trials in Cancer (Metastatic disease, Second-line therapy or greater, Combination therapy, Late-stage disease) in Taiwan, Netherlands, South Korea (PO) (NCT02890069)
  • 26 Oct 2016 Novartis Pharmaceuticals initiates enrolment in a phase I trial for Cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA and Spain (NCT02890069)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top